Mechanisms of clinically relevant drug interactions associated with tacrolimus.
about
The role of the pharmacist in the management of kidney transplant recipientsTacrolimus for the prevention and treatment of rejection of solid organ transplants.Determination of the most influential sources of variability in tacrolimus trough blood concentrations in adult liver transplant recipients: a bottom-up approachTacrolimus Blood Level Fluctuation Predisposes to Coexisting BK Virus Nephropathy and Acute Allograft RejectionPharmGKB summary: cyclosporine and tacrolimus pathwaysDevelopment and validation of a sensitive LC-MS/MS method for determination of tacrolimus on dried blood spots.Different influences on tacrolimus pharmacokinetics by coadministrations of zhi ke and zhi shi in ratsImproved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modellingDrug interactions in the hematopoietic stem cell transplant (HSCT) recipient: what every transplanter needs to know.The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients.Factors affecting variability in distribution of tacrolimus in liver transplant recipientsMDR1 haplotypes derived from exons 21 and 26 do not affect the steady-state pharmacokinetics of tacrolimus in renal transplant patients.Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling.The pharmacogenetics of calcineurin inhibitors: one step closer toward individualized immunosuppression?Management of children after renal transplantation: highlights for general pediatricians.Benefit of adjunctive tacrolimus in connective tissue disease-interstitial lung diseaseNovel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortiumFactors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants.Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelinesInterpreting tacrolimus concentrations during pregnancy and postpartum.External evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipients.Treatment of acute tacrolimus toxicity with phenytoin in solid organ transplant recipientsIntestinal permeability and its relevance for absorption and elimination.Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipientsStructural alterations in the seminiferous tubules of rats treated with immunosuppressor tacrolimusInfluence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients.Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvirTacrolimus placental transfer at delivery and neonatal exposure through breast milk.Effect of CYP3A4*22, CYP3A5*3, and CYP3A Combined Genotypes on Cyclosporine, Everolimus, and Tacrolimus Pharmacokinetics in Renal Transplantation.Visual loss associated with tacrolimus: case report and review of the literature.High tacrolimus blood concentrations early after lung transplantation and the risk of kidney injuryTacrolimus in the treatment of ocular diseases.The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation.Clinical and genetic factors affecting tacrolimus trough levels and drug-related outcomes in Korean kidney transplant recipients.Pharmacokinetics and Toxicity of Tacrolimus Early After Heart and Lung Transplantation.A systems-based approach to managing blood pressure in children following kidney transplantation.Clinical determinants of calcineurin inhibitor disposition: a mechanistic review.Sex differences in transplantation.Once-daily prolonged-release tacrolimus formulations for kidney transplantation: what the nephrologist needs to know.The CYP3A biomarker 4β-hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation.
P2860
Q26739666-C5B5F5E4-CAE3-4317-A035-BC9E53BC346FQ30278052-9E259A3B-3FE0-4DEC-9720-B77443646AA7Q33574176-AFCB2F5B-20FE-4602-9A3B-F8FF861A0C48Q33694700-4E9E9894-22F8-4093-B08D-AEF18D0E05BBQ33989902-3B9DC2D8-CCB8-4659-890C-90EFF5929CD1Q34380017-DD04973D-557B-4FAC-BDAE-6F252993A822Q34557606-0AECDE70-ED13-433D-B5AF-0E3A05D72765Q34571036-82C4267E-81D1-4C08-9369-FB27D593A6A3Q35608207-16C649F3-2781-464F-AD3D-36E242FDD3B3Q35612903-BEBC25A1-979A-4DB3-BFE7-D637D9FBA053Q35825985-B5AF4444-F73D-4C9B-8A8A-0AEF4EBD65BFQ35826490-A11F2D2D-5F4D-4C97-8104-25032E9315CAQ35826755-AC65B347-8A03-46DB-BDC8-F261CBFFD64FQ36186945-563D3F3F-4D04-49FF-BC14-3EE611F36473Q36508069-2D945A0F-067E-4822-BA7D-5456602F0E1EQ36598562-1FF49139-88DD-4424-B93B-A19B1D4016E6Q36630081-271FD614-5CFC-4621-AB75-AE27D74F456FQ36662912-B7A21373-1883-4FCE-9B10-7CA56CD06365Q36724093-7DB248D9-2D82-48F6-9920-1EDF430AEA9AQ36799909-577BAF6F-1F36-490E-A9A5-C2C37277B4ADQ36806621-B95AC3E1-469D-4DBE-9F47-2046E2CF1EFCQ36969224-5914377B-393A-4F85-AB62-722FFDBB185CQ36985043-57C63C18-DE3A-4069-ABBF-EAD6C0B9A92FQ37126092-C7B55C7A-C402-438D-8446-769ABDEF6A1FQ37139218-457F6651-D69B-4A2C-A587-3C74619D7823Q37247762-B80D707E-919A-4BD5-87BD-BD0809C2165EQ37257317-BF86E41B-7931-49B3-948F-4F518F1F0FCBQ37353469-DCF6C4A3-0B28-4F84-ABA8-D4BFEBFA1F8AQ37620393-662E9B97-CB5D-4706-A253-291C3B3B29A2Q37710106-10DB33AA-1AEE-4A55-B01E-C4CA7F4B6382Q37742226-FA35C15B-AEB8-4B4B-A52D-469555EA0DA9Q37858514-903B3BAF-3FE2-4224-B8C1-0A68D9D3CFC5Q38163945-55B32BA1-86F9-48E8-BFFF-0EC59D549FFBQ38467280-E0906BB3-E2B8-44EA-911A-F15C761E6298Q38520159-39152D57-1BEB-44EE-A651-663BC0592C47Q38611402-7E8B91A5-CBDC-4B72-B6C6-C347C757AD6BQ38748975-79798527-D5B4-486C-A99F-3419B2E65AC0Q38750337-13AD2754-EE59-4554-BC78-462BFBA07251Q38840168-BE088A63-8488-40EF-AB67-476D0B881BF3Q38986439-E0F4001B-45E2-4425-A129-F136E8E8DEFE
P2860
Mechanisms of clinically relevant drug interactions associated with tacrolimus.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Mechanisms of clinically relevant drug interactions associated with tacrolimus.
@ast
Mechanisms of clinically relevant drug interactions associated with tacrolimus.
@en
Mechanisms of clinically relevant drug interactions associated with tacrolimus.
@nl
type
label
Mechanisms of clinically relevant drug interactions associated with tacrolimus.
@ast
Mechanisms of clinically relevant drug interactions associated with tacrolimus.
@en
Mechanisms of clinically relevant drug interactions associated with tacrolimus.
@nl
prefLabel
Mechanisms of clinically relevant drug interactions associated with tacrolimus.
@ast
Mechanisms of clinically relevant drug interactions associated with tacrolimus.
@en
Mechanisms of clinically relevant drug interactions associated with tacrolimus.
@nl
P2093
P2860
P1476
Mechanisms of clinically relevant drug interactions associated with tacrolimus.
@en
P2093
Leslie Z Benet
Uwe Christians
Wolfgang Jacobsen
P2860
P304
P356
10.2165/00003088-200241110-00003
P577
2002-01-01T00:00:00Z
P6179
1025408957